The Role of IGF-1R in Pediatric Malignancies

被引:80
作者
Kim, Su Young [1 ]
Toretsky, Jeffrey A. [2 ]
Scher, Daniel [2 ]
Helman, Lee J. [1 ]
机构
[1] NCI, Ctr Canc Res, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA
[2] Georgetown Univ, Sch Med, Lombardi Comprehens Canc Ctr, Washington, DC USA
关键词
IGF-1R; Pediatric malignancy; Molecular targeting; Therapeutic antibody; GROWTH-FACTOR-I; AUTOCRINE GROWTH; EWINGS-SARCOMA; WILMS-TUMOR; FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; SIGNAL-TRANSDUCTION; ANTITUMOR-ACTIVITY; INSULIN; EXPRESSION;
D O I
10.1634/theoncologist.2008-0189
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The insulin-like growth factor (IGF) family consists of ligands (IGF-I, IGF-II, insulin), several receptors (including IGF-1R), and six binding proteins (IGFBP-1 through IGFBP-6). Members of this family regulate key cellular activities and they also play an important role in the development and progression of both adult and childhood cancers. Binding of a ligand to the receptor leads to its activation, followed by signal transduction along several pathways. In some childhood malignancies, IGF-1R can be activated by endocrine, autocrine, or paracrine mechanisms. Although mutations in IGF-1R have not been identified, this signaling pathway is upregulated in many childhood cancers. These findings have led to the development of a host of IGF-1R signaling modulators that are currently being tested in clinical trials. This review explores the role of IGF-1R in a range of childhood malignancies. The Oncologist 2009; 14: 83-91
引用
收藏
页码:83 / 91
页数:9
相关论文
共 72 条
[1]   Structure and function of the type 1 insulin-like growth factor receptor [J].
Adams, TE ;
Epa, VC ;
Garrett, TPJ ;
Ward, CW .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (07) :1050-1093
[2]   Molecular characterization of pediatric gastrointestinal stromal tumors [J].
Agaram, Narasimhan P. ;
Laquaglia, Michael P. ;
Ustun, Berrin ;
Guo, Tianhua ;
Wong, Grace C. ;
Socci, Nicholas D. ;
Maki, Robert G. ;
DeMatteo, Ronald P. ;
Besmer, Peter ;
Antonescu, Cristina R. .
CLINICAL CANCER RESEARCH, 2008, 14 (10) :3204-3215
[3]   A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors [J].
Atzori, F. ;
Tabernero, J. ;
Cervantes, A. ;
Botero, M. ;
Hsu, K. ;
Brown, H. ;
Hanley, W. ;
Macarulla, T. ;
Rosello, S. ;
Baselga, J. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[4]  
Ayalon D., 2001, Growth Hormone and IGF Research, V11, P289, DOI 10.1054/ghir.2001.0244
[5]   IGF-binding proteins - the pieces are failing into place [J].
Bach, LA ;
Headey, SJ ;
Norton, RS .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2005, 16 (05) :228-234
[6]   The role of insulin receptor isoforms and hybrid Insulin/IGF-I receptors in human cancer [J].
Belfiore, Antonino .
CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (07) :671-686
[7]   Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: Therapeutic prospects [J].
Benini, S ;
Manara, MC ;
Cerisano, V ;
Perdichizzi, S ;
Strammiello, R ;
Serra, M ;
Picci, P ;
Scotlandi, K .
INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (03) :358-366
[8]   Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors [J].
Bjornsson, Hans T. ;
Brown, Lindsey J. ;
Fallin, M. Danielle ;
Rongione, Michael A. ;
Bibikova, Marina ;
Wickham, Eliza ;
Fan, Jian-Bing ;
Feinberg, Andrew P. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (16) :1270-1273
[9]  
Burrow S, 1998, J SURG ONCOL, V69, P21, DOI 10.1002/(SICI)1096-9098(199809)69:1<21::AID-JSO5>3.0.CO
[10]  
2-M